PD-1 and PD-L1 Inhibitors Market Growth Driven by Advancements in Immunotherapy and Regulatory Approvals

The PD-1 and PD-L1 inhibitors market is projected to grow at a CAGR of 16.10% from 2025 to 2034, driven by the rising incidence of cancer and increasing adoption of immunotherapies. The market was valued at USD 54.90 Billion in 2024 and is expected to reach USD 244.28 Billion by 2034. Regulatory approvals, expanding treatment options, and advancements in liquid biopsy and mRNA-based innovations are key drivers of market growth.

The global PD-1 and PD-L1 inhibitors market, valued at USD 54.90 billion in 2024, is projected to grow at a CAGR of 16.10% from 2025 to 2034, reaching USD 244.28 billion by 2034. This robust growth is fueled by the rising incidence of cancer and the increasing adoption of immunotherapies [1].

Key drivers of market expansion include rising regulatory approvals and the adoption of immunotherapies like Imfinzi and TEVIMBRA. For instance, in August 2024, the AEGEAN Phase III trial demonstrated that an Imfinzi (durvalumab)-based regimen reduced the risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone. Consequently, the U.S. FDA approved Imfinzi in combination with chemotherapy for early-stage non-small cell lung cancer (NSCLC), which is expected to expand the use of PD-L1 inhibitors in early-stage cancer management [1].

Moreover, the approval of TEVIMBRA (tislelizumab-jsgr) by the U.S. FDA in March 2024 as a monotherapy for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) has significantly expanded treatment options, further driving market growth. This approval is anticipated to increase accessibility to immunotherapies and stimulate competitive advancements in the market [1].

Liquid biopsy advancements and mRNA-based innovations are also contributing to market growth. The launch of the Portrait PD-L1 test by Angle in November 2023, which evaluates PD-L1 protein expression on circulating tumour cells (CTCs), is a notable example. This innovation enhances non-invasive biomarker detection, enabling precision oncology and accelerating drug development. Additionally, the INTerpath-009 trial initiated by Merck and Moderna in October 2024 is exploring the synergy between PD-1 inhibitors and mRNA-based neoantigen therapies, which could redefine oncology treatment landscapes [1].

The approval of UNLOXCYT (cosibelimab-ipdl) by Checkpoint Therapeutics in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) further expands the clinical applications of PD-L1 inhibitors. This approval is expected to drive market expansion by increasing competition and encouraging further research into PD-L1-targeted therapies for other solid tumours [1].

In December 2024, Bristol Myers Squibb secured FDA approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a subcutaneous PD-1 inhibitor formulation for various solid tumours. This approval enables a more convenient, non-inferior alternative to intravenous administration, enhancing patient compliance and reducing treatment burden [1].

The market is expected to continue its upward trajectory, driven by these innovations and regulatory approvals. Key players in the market include Bristol-Myers Squibb, Merck & Co., Sanofi, Novartis, AstraZeneca, Pfizer, Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Ottobock Healthcare, and Jiangsu Hengrui Medicine Co., Ltd. [1].

References:
[1] https://finance.yahoo.com/news/pd-1-pd-l1-inhibitors-144700979.html